CD44 is a multifunctional transmembrane glycoprotein that is expressed in many cancers and can regulate invasion and metastasis. CD44 can interact with a multitude of ligands to promote metastasis and invasion. CD44 is also a known cancer stem cell marker. Due to alternative splicing, CD44 can exist in multiple isoforms besides standard CD44 isoform. Recent studies have shown that CD44 can be proteolytically cleaved into CD44-intracellular domain (ICD). Specifically, this cleavage product ICD translocates into the nucleus to activate transcription of a variety of genes that are critical to inflammation, cell survival, glycolysis, and cancer metastasis.
{"title":"https://researchopenworld.com/cd44-cleavage-product-cd44-intracellular-domain-regulates-gene-transcription-and-tumorigenesis/#","authors":"Linda T. Senbanjo, M. Chellaiah","doi":"10.31038/cst.2019445","DOIUrl":"https://doi.org/10.31038/cst.2019445","url":null,"abstract":"CD44 is a multifunctional transmembrane glycoprotein that is expressed in many cancers and can regulate invasion and metastasis. CD44 can interact with a multitude of ligands to promote metastasis and invasion. CD44 is also a known cancer stem cell marker. Due to alternative splicing, CD44 can exist in multiple isoforms besides standard CD44 isoform. Recent studies have shown that CD44 can be proteolytically cleaved into CD44-intracellular domain (ICD). Specifically, this cleavage product ICD translocates into the nucleus to activate transcription of a variety of genes that are critical to inflammation, cell survival, glycolysis, and cancer metastasis.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86739443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Faizanahmed Munshi, Brian M Shinder, Evita Sadimin, Tina M Mayer, Eric A Singer
Prostate cancer metastases are commonly seen in the skeleton, lymph nodes, lungs, or liver, and are associated with a poor five-year survival rate. Renal pelvis and ureteral metastasis are exceedingly uncommon and can present with obstructive symptoms or as an asymptomatic mass on imaging. We report the case of a 60-year-old patient who was initially diagnosed with prostate adenocarcinoma and experienced eventual metastasis to the right renal pelvis and proximal ureter. Following the diagnosis, he was started on docetaxel and pembrolizumab as part of a clinical trial protocol. A high index of suspicion and thorough metastatic work-up is necessary when patients with prostate cancer present with symptoms of obstructive uropathy or new visceral disease is identified.
{"title":"Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature.","authors":"Faizanahmed Munshi, Brian M Shinder, Evita Sadimin, Tina M Mayer, Eric A Singer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prostate cancer metastases are commonly seen in the skeleton, lymph nodes, lungs, or liver, and are associated with a poor five-year survival rate. Renal pelvis and ureteral metastasis are exceedingly uncommon and can present with obstructive symptoms or as an asymptomatic mass on imaging. We report the case of a 60-year-old patient who was initially diagnosed with prostate adenocarcinoma and experienced eventual metastasis to the right renal pelvis and proximal ureter. Following the diagnosis, he was started on docetaxel and pembrolizumab as part of a clinical trial protocol. A high index of suspicion and thorough metastatic work-up is necessary when patients with prostate cancer present with symptoms of obstructive uropathy or new visceral disease is identified.</p>","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"4 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059776/pdf/nihms-1048180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37717530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nucleolin, a major protein of the nucleolus which is required for cell proliferation is the subject of numerous studies in the field of oncology. Many studies suggest that the level of expression of nucleolin and its cellular localization could be an indication of the clinical outcome in several cancers. Quite logically for a protein required for the cancer cells to increased protein synthesis, a correlation between the high level of nucleolin expression and the poor prognosis of the patients is often reported. Unexpectedly, in several studies it was also found that a low nucleolin expression could be also associated with an unfavorable prognosis. In these commentary I discuss these studies and the possible implications for using nucleolin as a prognostic marker in oncology.
{"title":"Nucleolin: a prognostic marker in cancer?","authors":"P. Bouvet","doi":"10.31038/cst.2019118","DOIUrl":"https://doi.org/10.31038/cst.2019118","url":null,"abstract":"Nucleolin, a major protein of the nucleolus which is required for cell proliferation is the subject of numerous studies in the field of oncology. Many studies suggest that the level of expression of nucleolin and its cellular localization could be an indication of the clinical outcome in several cancers. Quite logically for a protein required for the cancer cells to increased protein synthesis, a correlation between the high level of nucleolin expression and the poor prognosis of the patients is often reported. Unexpectedly, in several studies it was also found that a low nucleolin expression could be also associated with an unfavorable prognosis. In these commentary I discuss these studies and the possible implications for using nucleolin as a prognostic marker in oncology.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81534866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Contemporary academic (conventional) medicine, based on current advancements in life sciences and applying evidence based efficacy and safety principles, has evolved from ancient cultures of well-being and healing practices, which originated in prehistoric times, and it co-exists with their ethno-medicine remnants conveniently described as complementary and alternative medicine (CAM) [1, 2]. Global healthcare crisis, which has led to acceptance and even encouragement of CAM practices as an aid to conventional medicine, is a phenomenon of great complexity, comprising processes of various speed and dynamics. In this mini-review we’ll limit discussion to influence of IT and novel scientific knowledge dissemination systems, such as Open Science, to self-medication applied with legally available biologically active substances, but not limited to the OTC drugs.
{"title":"https://researchopenworld.com/open-space-knowledge-and-data-and-their-influence-on-natural-products-based-self-medication-trends/#","authors":"G. Grynkiewicz, W. Maruszak","doi":"10.31038/cst.2019435","DOIUrl":"https://doi.org/10.31038/cst.2019435","url":null,"abstract":"Contemporary academic (conventional) medicine, based on current advancements in life sciences and applying evidence based efficacy and safety principles, has evolved from ancient cultures of well-being and healing practices, which originated in prehistoric times, and it co-exists with their ethno-medicine remnants conveniently described as complementary and alternative medicine (CAM) [1, 2]. Global healthcare crisis, which has led to acceptance and even encouragement of CAM practices as an aid to conventional medicine, is a phenomenon of great complexity, comprising processes of various speed and dynamics. In this mini-review we’ll limit discussion to influence of IT and novel scientific knowledge dissemination systems, such as Open Science, to self-medication applied with legally available biologically active substances, but not limited to the OTC drugs.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80244812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of epithelial renal tumor considered as a low-grade neoplasm by the World Health Organization. Therefore, partial or radical nephrectomy may be curative whether in early stages. Less than a hundred of these tumors have been reported with gross and microscopic features, immunohistochemical profile and clinical findings. Here we report two cases of MTSCC with emphasis on the clinicopathological correlations according to postoperative findings. Both patients underwent a video-assisted resection of the kidney. No recurrence or metastasis was observed during the follow-up.
{"title":"Renal Mucinous Tubular and Spindle Cell Carcinoma: A Report of Two Cases and Literature Review","authors":"B. Dornelas","doi":"10.31038/cst.1000418","DOIUrl":"https://doi.org/10.31038/cst.1000418","url":null,"abstract":"Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of epithelial renal tumor considered as a low-grade neoplasm by the World Health Organization. Therefore, partial or radical nephrectomy may be curative whether in early stages. Less than a hundred of these tumors have been reported with gross and microscopic features, immunohistochemical profile and clinical findings. Here we report two cases of MTSCC with emphasis on the clinicopathological correlations according to postoperative findings. Both patients underwent a video-assisted resection of the kidney. No recurrence or metastasis was observed during the follow-up.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87397042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：